Double-Blind, Placebo-Controlled Study of Amantadine Hydrochloride in the Treatment of Children With Autistic Disorder

King, Bryan H.; Wright, D.M.; Handen, Benjamin L.; Sikich, Linmarie; Zimmerman, Andrew W.; McMahon, William M.; Cantwell, Erin; Davanzo, Pablo; Dourish, C T; Dykens, Elisabeth M.; Hooper, Stephen R.; Jaselskis, Catherine; Leventhal, Bennett L.; Levitt, Jennifer G.; Lord, Catherine; Lubetsky, Martin J.; Myers, Scott M.; Ozonoff, Sally J; Shah, Bhavik; Snape, Michael; Shernoff, Elisa S.; Williamson, Kwanna; Cook, Edwin H.

doi:10.1097/00004583-200106000-00010

Cited by 174 publications

(108 citation statements)

References 23 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…A controlled study using amantidine in 39 autistic patients between 5 and 15 years suggests a positive effect on irritability and hyperactivity, but the sample size might have been extremely small. 124 Lamotrigine, even at high serum levels, did not show significant differences comparatively to placebo. 125 No data are available that support the use of naltrexone to reduce self-injurious behaviors.…”

Section: Pharmacotherapymentioning

confidence: 87%

Autismo e doenças invasivas de desenvolvimento

Gadia¹,

Tuchman²,

Rotta³

2004

J. Pediatr. (Rio J.)

119

View full text Add to dashboard Cite

Objective: To review the current knowledge on neurobiological aspects of autism and pervasive developmental disorders, as well as to provide pediatricians with up to date information on diagnosis and treatment of autism. Sources of data: Review of MEDLINE and Internet.Summary of the findings: Autism is the 3rd developmental disorder, with an incidence of 40 to 130/100,000 individuals. Diagnosis is based on clinical findings, following DSM IV criteria. Neuroimaging, investigation of fetal neurological status, and genetic investigation contribute towards a better understanding of the neurobiology of autism. Conclusion:Pediatricians are the first health professional to come in contact with patients with autism. Thus, they should be able to diagnose and to coordinate the multidisciplinary treatment of these patients.J Pediatr (Rio J). 2004;80(2 Suppl):S83-S94: Autism, child behavior, child development.

show abstract

Section: Pharmacotherapymentioning

confidence: 87%

Autismo e doenças invasivas de desenvolvimento

Gadia¹,

Tuchman²,

Rotta³

2004

J. Pediatr. (Rio J.)

119

View full text Add to dashboard Cite

show abstract

“…33 Amantadine, a dopaminergic agent used for treating Parkinson's disease, was also indistinguishable from placebo. 40 Omega-3 fatty acid 36 (antioxidant) and secretin 37 (endogenous hormone regulating secretions from the stomach and pancreas) also showed no significant advantage over placebo.…”

Section: Figurementioning

confidence: 98%

Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis

et al. 2016

View full text Add to dashboard Cite

BACKGROUND: Autism spectrum disorder (ASD) is increasingly recognized as a public health issue. Irritability and aggression (IA) often negatively affect the lives of people with ASD and their families. Although many medications have been tested for IA in ASDs in randomized controlled trials (RCTs), critical quantitative analyses of these trials are lacking in the literature. OBJECTIVES:To systematically review and quantitatively analyze the efficacy and safety of pharmacologic treatments for IA in youth with ASD.DATA SOURCES: Studies were identified from Medline, PsycINFO, Embase, and review articles. METHODS:Original articles on placebo-controlled RCTs of pharmacologic treatments of IA in youth age 2 to 17 years with ASD were included. Data items included study design, study goals, details of study participants, details of intervention, study results, statistical methods, side effects, and risks of bias. The primary study outcome measure was the effect size of reduction in the Aberrant Behavioral Checklist-Irritability (ABC-I) scores in the medication group, as compared with placebo, in RCTs using parallel groups design. RESULTS:Forty-six RCTs were identified. Compared with placebo, 3 compounds resulted in significant improvement in ABC-I at the end of treatment. Risperidone and aripiprazole were found to be the most effective, with the largest effect sizes. Sedation, extrapyramidal sides effects, and weight gain were assessed quantitatively. CONCLUSIONS:Although risperidone and aripiprazole have the strongest evidence in reducing ABC-I in youth with ASD, a few other compounds also showed significant efficacy with fewer potential side effects and adverse reactions in single studies.

show abstract

“…As with behavioral rigidity and inflexibility, similar models for stereotypy and obsessive-compulsive disorder have been proposed [72]. Stereotypy also may be closely related to tic disorders and Parkinson disease, however, in which repetitive behaviors emerge from impairment in dopaminergic [73] and glutamaturgic systems [74]. There are also interesting analogs to L-dopa toxicity in Parkinson disease [75].…”

Section: Stereotypies and Perseverationmentioning

confidence: 97%

Strategies for pharmacologic treatment of high functioning autism and Asperger syndrome

Towbin

2003

Child and Adolescent Psychiatric Clinics of North America

View full text Add to dashboard Cite

Double-Blind, Placebo-Controlled Study of Amantadine Hydrochloride in the Treatment of Children With Autistic Disorder

Cited by 174 publications

References 23 publications

Autismo e doenças invasivas de desenvolvimento

Autismo e doenças invasivas de desenvolvimento

Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis

Strategies for pharmacologic treatment of high functioning autism and Asperger syndrome

Contact Info

Product

Resources

About